While Sarepta Therapeutics Inc has underperformed by -42.12%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT fell by -82.55%, with highs and lows ranging from $173.25 to $34.10, whereas the simple moving average fell by -78.62% in the last 200 days.
On June 16, 2025, Piper Sandler Downgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) to Neutral. A report published by Morgan Stanley on June 16, 2025, Downgraded its rating to ‘Equal-Weight’ for SRPT. H.C. Wainwright also Downgraded SRPT shares as ‘Sell’, setting a target price of $10 on the company’s shares in a report dated June 16, 2025. BofA Securities June 16, 2025d its ‘Buy’ rating to ‘Neutral’ for SRPT, as published in its report on June 16, 2025. BMO Capital Markets’s report from June 16, 2025 suggests a price prediction of $70 for SRPT shares, giving the stock a ‘Market Perform’ rating. Scotiabank also rated the stock as ‘Sector Outperform’.
Analysis of Sarepta Therapeutics Inc (SRPT)
Further, the quarter-over-quarter increase in sales is 80.15%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Sarepta Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -23.61% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.46, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 3.85M can be a very valuable indicator of volatility for SRPT stock. On a monthly basis, the volatility of the stock is set at 12.80%, whereas on a weekly basis, it is put at 26.08%, with a loss of -47.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $69.68, showing growth from the present price of $20.94, which can serve as yet another indication of whether SRPT is worth investing in or should be passed over.
How Do You Analyze Sarepta Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.99%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SRPT shares are owned by institutional investors to the tune of 90.14% at present.
